236 related articles for article (PubMed ID: 18617596)
1. The contribution of different androgen receptor domains to receptor dimerization and signaling.
Centenera MM; Harris JM; Tilley WD; Butler LM
Mol Endocrinol; 2008 Nov; 22(11):2373-82. PubMed ID: 18617596
[TBL] [Abstract][Full Text] [Related]
2. Stepwise androgen receptor dimerization.
van Royen ME; van Cappellen WA; de Vos C; Houtsmuller AB; Trapman J
J Cell Sci; 2012 Apr; 125(Pt 8):1970-9. PubMed ID: 22328501
[TBL] [Abstract][Full Text] [Related]
3. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
4. Complete androgen insensitivity syndrome caused by a novel mutation in the ligand-binding domain of the androgen receptor: functional characterization.
Rosa S; Biason-Lauber A; Mongan NP; Navratil F; Schoenle EJ
J Clin Endocrinol Metab; 2002 Sep; 87(9):4378-82. PubMed ID: 12213902
[TBL] [Abstract][Full Text] [Related]
5. [The androgen receptor: molecular pathology].
Sultan Ch; Gobinet J; Terouanne B; Paris F; Belon Ch; Jalaguier S; Georget V; Poujol N; Auzou G; Lumbroso S
J Soc Biol; 2002; 196(3):223-40. PubMed ID: 12465595
[TBL] [Abstract][Full Text] [Related]
6. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
[TBL] [Abstract][Full Text] [Related]
8. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
[TBL] [Abstract][Full Text] [Related]
9. Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.
Butler LM; Centenera MM; Neufing PJ; Buchanan G; Choong CS; Ricciardelli C; Saint K; Lee M; Ochnik A; Yang M; Brown MP; Tilley WD
Mol Endocrinol; 2006 May; 20(5):1009-24. PubMed ID: 16423882
[TBL] [Abstract][Full Text] [Related]
10. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
Duff J; McEwan IJ
Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
[TBL] [Abstract][Full Text] [Related]
11. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability.
Zhou ZX; Lane MV; Kemppainen JA; French FS; Wilson EM
Mol Endocrinol; 1995 Feb; 9(2):208-18. PubMed ID: 7776971
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
[TBL] [Abstract][Full Text] [Related]
15. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
16. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
[TBL] [Abstract][Full Text] [Related]
17. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
18. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
Zhou ZX; He B; Hall SH; Wilson EM; French FS
Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
[TBL] [Abstract][Full Text] [Related]
19. The androgen receptor: unlocking the secrets of its unique transactivation domain.
Shen HC; Coetzee GA
Vitam Horm; 2005; 71():301-19. PubMed ID: 16112272
[TBL] [Abstract][Full Text] [Related]
20. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication.
Lee DK; Chang C
J Clin Endocrinol Metab; 2003 Sep; 88(9):4043-54. PubMed ID: 12970260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
